Maxcyte (MXCT) Accumulated Expenses (2020 - 2026)

Maxcyte (MXCT) has 7 years of Accumulated Expenses data on file, last reported at $4.4 million in Q1 2026.

• Accumulated Expenses for Q1 2026 came in at $4.4 million, down 13.15% year-over-year; the trailing twelve-month figure through Mar 2026 was $4.4 million (down 13.15% YoY), and the FY2025 annual result was $7.8 million, down 5.9% from the prior year.
• Accumulated Expenses slipped to $4.4 million in Q1 2026 per MXCT's latest filing, from $7.8 million in the prior quarter.
• Over five years, Accumulated Expenses peaked at $11.3 million in Q4 2023 and troughed at $3.9 million in Q1 2022.
• A 5-year average of $7.3 million and a median of $7.8 million in 2025 frame the typical range for Accumulated Expenses.
• The sharpest annual moves came in 2023 and 2024: Accumulated Expenses jumped 78.59% in 2023, then decreased 26.33% in 2024.
• A 5-year view of Accumulated Expenses shows it stood at $8.3 million in 2022, then jumped by 36.35% to $11.3 million in 2023, then declined by 26.33% to $8.3 million in 2024, then fell by 5.9% to $7.8 million in 2025, then tumbled by 44.05% to $4.4 million in 2026.
• Business Quant data shows MXCT's Accumulated Expenses at $4.4 million in Q1 2026, $7.8 million in Q4 2025, and $8.3 million in Q3 2025.